(VIANEWS) – The NASDAQ opens in less than five hours and Inovio Pharmaceuticals‘s pre-market value is already 4.35% down.

Inovio Pharmaceuticals’s last close was $1.73, 77.8% below its 52-week high of $7.77.

The last session, NASDAQ finished with Inovio Pharmaceuticals (INO) rising 2.68% to $1.73. NASDAQ dropped 1.51% to $10,575.62, after two sequential sessions in a row of losses, on what was an all-around negative trend trading session.

Why is Inovio Pharmaceuticals Stock Going up?

Inovio Pharmaceuticals, or INO, is a biotech that focuses on developing vaccines for diseases affecting the reproductive system. It has a drug in phase 3 testing that is intended to treat a precancerous disease of the cervix. It has partnered with private biopharma ApolloBio to bring its drug to market. However, Inovio is not yet profitable and expects to continue losing money for the foreseeable future. Despite this, management is cutting costs in order to increase the runway for drug approval and decrease R&D spending on non-core projects.

Considering this recent data, it’s possible that INO stock could hit higher levels in the future. After all, INO’s stock price has fallen by 17% in the last month. Nonetheless, historical performance suggests that there is a high probability that the stock will bounce back. For example, 269 of 412 instances in which INO’s stock fell by 17% or more ended in a rise over the following one month period. This pattern suggests that there is a 65% chance that the stock will rise again.

While Inovio hasn’t exactly been a favorite among investors, the company’s focus on COVID-19 could lead to a massive rally in 2020 if its product is approved. While this vaccine is still a ways off, investors can’t ignore its potential to help people who are infected with the disease.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These drugs are used to protect and treat people against diseases such as cancer, human papillomavirus, and other infectious diseases. The DNA medicines platform utilizes precisely-designed SynCon to identify and optimize DNA sequences of target antigens. CELLECTRA smart device technology facilitates the delivery of DNA plasmids. It plans clinical trials of DNA medicines to treat HPV-associated diseases, including anal and cervical dysplasia, vulvar and cervical precancers; HPV associated cancers such as cervical and anal papillomatosis, head and neck cancer, vaginal cancer, HIV, Ebola, Middle East Respiratory syndrome (MERS), and Lassa fever. ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, (DARPA), Defense Advanced Research Projects Agency, Defense Advanced Research Projects Agency, Department of Defense (DoD), HIV Vaccines Trial Network, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals, Thero Fisher Scientific, Thermo Fisher Military Institute of Research, The Wistar Institute of Research, University of Research, Walter Reed Army Institute of Research, University of Research, University of Research, University of Research, University of Research, University of Research, The Wistar Institute of Research, University of Research, University of Research, University of Research, Thermo Fisher, Thermo Fisher Research, and Thermo Fisher s, Thermo Fisher ' and Thermo To support the investigational DNA vaccine, INO-4800, for COVID-19, Richter-Helm BioLogics GmbH & Co. KG has been entered into an agreement. The partnership also includes International Vaccine Institute (Seoul National University Hospital) and Regeneron Pharmaceuticals. Plymouth Meeting is the headquarters of this company, which was established in 1979.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.073.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -70.1%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 20.5% and 3.4%, respectively.

Sales Growth

Inovio Pharmaceuticals’s sales growth is 90.5% for the ongoing quarter and negative 45.4% for the next.

Moving Average

Inovio Pharmaceuticals’s value is way below its 50-day moving average of $2.16 and way below its 200-day moving average of $2.92.

More news about Inovio Pharmaceuticals (INO).

LEAVE A REPLY

Please enter your comment!
Please enter your name here